Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Gossamer Bio to host virtual investor day » 14:25
10/11/21
10/11
14:25
10/11/21
14:25
GOSS

Gossamer Bio

$13.56 /

+0.985 (+7.83%)

Virtual Investor Day to…

Virtual Investor Day to be held on October 11 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
GOSS Gossamer Bio
$13.56 /

+0.985 (+7.83%)

GOSS Gossamer Bio
$13.56 /

+0.985 (+7.83%)

09/20/21 Piper Sandler
Gossamer Bio assumed with an Overweight at Piper Sandler
03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
GOSS Gossamer Bio
$13.56 /

+0.985 (+7.83%)

  • 30
    Oct
Conference/Events
Gossamer Bio to host virtual investor day » 08:54
10/11/21
10/11
08:54
10/11/21
08:54
GOSS

Gossamer Bio

$12.58 /

+0.275 (+2.24%)

Virtual Investor Day to…

Virtual Investor Day to be held on October 11 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
GOSS Gossamer Bio
$12.58 /

+0.275 (+2.24%)

GOSS Gossamer Bio
$12.58 /

+0.275 (+2.24%)

09/20/21 Piper Sandler
Gossamer Bio assumed with an Overweight at Piper Sandler
03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
GOSS Gossamer Bio
$12.58 /

+0.275 (+2.24%)

  • 30
    Oct
Hot Stocks
Gossamer Bio adds two CNS-penetrant BTK inhibitors to product candidate pipeline » 08:52
10/11/21
10/11
08:52
10/11/21
08:52
GOSS

Gossamer Bio

$12.58 /

+0.275 (+2.24%)

Gossamer Bio announced…

Gossamer Bio announced the addition of two CNS-penetrant Bruton's tyrosine kinase, or BTK, inhibitors to its product candidate pipeline. Gossamer plans to initiate first-in-human studies of the first of these candidates, GB5121, in Q4 of 2021. Gossamer intends to develop GB5121 in CNS-oncology indications, including relapsed / refractory primary CNS lymphoma for which a potentially registrational Phase 1b / 2 study is expected to initiate in the first half of 2022. The second product candidate, GB7208, is currently in IND-enabling studies and is expected to enter the clinic in the second half of 2022. In a BTK-dependent pre-clinical disease model, GB7208 demonstrated superior outcomes vs. tolebrutinib, a BTK inhibitor being studied in a broad Phase 3 program for multiple sclerosis.

ShowHide Related Items >><<
GOSS Gossamer Bio
$12.58 /

+0.275 (+2.24%)

GOSS Gossamer Bio
$12.58 /

+0.275 (+2.24%)

09/20/21 Piper Sandler
Gossamer Bio assumed with an Overweight at Piper Sandler
03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
GOSS Gossamer Bio
$12.58 /

+0.275 (+2.24%)

  • 30
    Oct
Over a month ago
Hot Stocks
Gossamer Bio appoints Bryan Giraudo as COO » 08:58
09/21/21
09/21
08:58
09/21/21
08:58
GOSS

Gossamer Bio

$10.26 /

-0.29 (-2.75%)

Gossamer Bio announced…

Gossamer Bio announced that Bryan Giraudo has been appointed COO in addition to his continued role as CFO. Giraudo joined Gossamer in May 2018 as its CFO. Prior to joining Gossamer Bio, Giraudo was a senior managing director at Leerink Partners, now known as SVB Leerink, from 2009 to April 2018.

ShowHide Related Items >><<
GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

09/20/21 Piper Sandler
Gossamer Bio assumed with an Overweight at Piper Sandler
03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

  • 30
    Oct
Initiation
Gossamer Bio assumed with an Overweight at Piper Sandler » 21:25
09/20/21
09/20
21:25
09/20/21
21:25
GOSS

Gossamer Bio

$10.26 /

-0.29 (-2.75%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi assumed coverage of Gossamer Bio with an Overweight rating and $26 price target. The analyst has "strong conviction" on both the company's clinical stage assets: Seralutinib for pulmonary arterial hypertension and GB004 for ulcerative colitis. The analyst is positive on the shares into the two second half of 2021 data readouts.

ShowHide Related Items >><<
GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$10.26 /

-0.29 (-2.75%)

  • 30
    Oct
Earnings
Gossamer Bio reports Q2 EPS (80c), consensus (76c) » 16:04
08/09/21
08/09
16:04
08/09/21
16:04
GOSS

Gossamer Bio

$8.40 /

+0.14 (+1.69%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities as of June 30, 2021, were $405.9M. The Company expects the combination of current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2023.

ShowHide Related Items >><<
GOSS Gossamer Bio
$8.40 /

+0.14 (+1.69%)

GOSS Gossamer Bio
$8.40 /

+0.14 (+1.69%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$8.40 /

+0.14 (+1.69%)

  • 30
    Oct
Over a quarter ago
Hot Stocks
Gossamer Bio names Richard Aranda as Chief Medical Officer » 16:02
06/21/21
06/21
16:02
06/21/21
16:02
GOSS

Gossamer Bio

$8.41 /

-0.16 (-1.87%)

Gossamer Bio announced…

Gossamer Bio announced that, Richard Aranda, M.D., previously Senior Vice President and Head of Clinical Development, will be promoted to Chief Medical Officer. Dr. Aranda joined Gossamer in February 2018 with responsibilities including oversight of Clinical Pharmacology, Translational Medicine, and Pharmacovigilance.

ShowHide Related Items >><<
GOSS Gossamer Bio
$8.41 /

-0.16 (-1.87%)

GOSS Gossamer Bio
$8.41 /

-0.16 (-1.87%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$8.41 /

-0.16 (-1.87%)

  • 30
    Oct
Earnings
Gossamer Bio reports Q1 EPS (78c), consensus (75c) » 07:41
05/06/21
05/06
07:41
05/06/21
07:41
GOSS

Gossamer Bio

$8.35 /

-0.09 (-1.07%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities as of March 31, 2021, were $453.3 million. The Company expects the combination of current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2023.

ShowHide Related Items >><<
GOSS Gossamer Bio
$8.35 /

-0.09 (-1.07%)

GOSS Gossamer Bio
$8.35 /

-0.09 (-1.07%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$8.35 /

-0.09 (-1.07%)

  • 30
    Oct
  • 19
    May
Conference/Events
Gossamer Bio management to meet virtually with Evercore ISI » 04:55
04/27/21
04/27
04:55
04/27/21
04:55
GOSS

Gossamer Bio

$8.76 /

+0.49 (+5.93%)

Virtual Meeting to be…

Virtual Meeting to be held on April 27 hosted by Evercore ISI.

ShowHide Related Items >><<
GOSS Gossamer Bio
$8.76 /

+0.49 (+5.93%)

GOSS Gossamer Bio
$8.76 /

+0.49 (+5.93%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$8.76 /

+0.49 (+5.93%)

  • 30
    Oct
  • 19
    May
Conference/Events
Gossamer Bio management to meet virtually with Evercore ISI » 11:40
04/22/21
04/22
11:40
04/22/21
11:40
GOSS

Gossamer Bio

$8.58 /

+0.17 (+2.02%)

Virtual Meeting to be…

Virtual Meeting to be held on April 27 hosted by Evercore ISI.

ShowHide Related Items >><<
GOSS Gossamer Bio
$8.58 /

+0.17 (+2.02%)

GOSS Gossamer Bio
$8.58 /

+0.17 (+2.02%)

03/24/21 H.C. Wainwright
Gossamer Bio price target raised to $25 from $24 at H.C. Wainwright
12/17/20 H.C. Wainwright
Gossamer Bio price target raised to $24 from $15 at H.C. Wainwright
10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
GOSS Gossamer Bio
$8.58 /

+0.17 (+2.02%)

  • 30
    Oct
  • 19
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.